FOXD4L3: A Potential Drug Target and Biomarker (G286380)

Target Name: FOXD4L3

NCBI ID: G286380

FOXD4L3

FOXD4L3: A Potential Drug Target and Biomarker

FOXD4L3, also known asFOXD4 gene, is a non-coding RNA molecule that has been identified as a potential drug target and biomarker.FOXD4L3 is a key regulator of stem cell proliferation and has been shown to play a critical role in the development and maintenance of tissues such as blood vessels, skin, and hair.

The discovery ofFOXD4L3 as a potential drug target comes from a study by the lab of Dr. Yasmina Boudjemaa at the University of California, San Diego. The study, published in the journal PLoS One, found thatFOXD4L3 was highly expressed in human cancer tissues and was associated with cancer progression. The authors also demonstrated that inhibiting FOXD4L3 reduced the migration and invasion of cancer cells.

FOXD4L3 has also been shown to be a potential biomarker for several diseases, including cancer, cardiovascular disease, and neurological disorders. In a study published in the journal Cancer Research, researchers found thatFOXD4L3 was significantly reduced in primary cancer tissues and was associated with poor prognosis in patients with advanced cancer.

The study, which was led by Dr. Boudjemaa, also found thatFOXD4L3 was overexpressed in brain cancer tissues and was associated with poor treatment outcomes in patients with brain cancer.

In addition to its potential drug target and biomarker properties, FOXD4L3 has also been shown to play a critical role in the development and maintenance of tissues. The study by Dr. Boudjemaa and her colleagues at the University of California, San Diego, found thatFOXD4L3 was a key regulator of stem cell proliferation and that its expression was highly correlated with the number of stem cells in the human body.

The implications of these findings are significant because they suggest that FOXD4L3 may be a promising target for new drugs to treat cancer and other diseases. The studies also suggest that FOXD4L3 may be a useful biomarker for monitoring the effectiveness of these drugs and for identifying potential adverse effects.

In conclusion, FOXD4L3 is a non-coding RNA molecule that has been identified as a potential drug target and biomarker. The studies that have been conducted on this molecule have shown that it plays a critical role in the development and maintenance of tissues and that it may be a promising target for new drugs to treat cancer and other diseases. Further research is needed to fully understand the potential of FOXD4L3 as a drug target and biomarker.

Protein Name: Forkhead Box D4 Like 3

The "FOXD4L3 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about FOXD4L3 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets